Expert Opinion on Pharmacotherapy最新文献_第10页

Oral mucosal toxicities in oncology. 肿瘤中的口腔黏膜毒性。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-03-01 Epub Date: 2025-02-13 DOI: 10.1080/14656566.2025.2464106

Alessandro Villa, Michele Lodolo, Stephen Sonis

{"title":"Oral mucosal toxicities in oncology.","authors":"Alessandro Villa, Michele Lodolo, Stephen Sonis","doi":"10.1080/14656566.2025.2464106","DOIUrl":"10.1080/14656566.2025.2464106","url":null,"abstract":"Introduction: Oral mucosal toxicities are serious complications associated with conventional cytotoxic radiation and drug-based cancer regimens, and novel treatments such as immunotherapy and targeted agents. These toxicities, including oral mucositis, mammalian target of rapamycin inhibitor-associated stomatitis, oral immune-related adverse events, oral lichenoid lesions secondary to rituximab or imatinib, and geographic tongue associated with bevacizumab, sorafenib, sunitinib, or axitinib, can lead to significant morbidity, potentially compromising cancer treatment outcomes by necessitating treatment dose reductions, interruptions, or discontinuation.Areas covered: This review discusses the epidemiology, clinical presentation, pathobiology, and current management strategies for these oral mucosal toxicities.Expert opinion: With the evolution of novel cancer therapies, including immunotherapy and targeted agents, oral mucosal toxicities have become more prevalent, presenting significant management challenges. Advances in understanding the pathobiology of these complications have led to the development of promising therapeutic strategies. However, variability in patient responses underscores the need for precision medicine approaches that tailor treatments to individual molecular and immunological profiles. While the standardization of clinical trials has improved the comparability of interventions, therapies must be rigorously tested to ensure they do not interfere with the oncologic efficacy of cancer treatments. Ongoing research is essential to refine preventive and therapeutic approaches.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"481-489"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Selective progesterone receptor modulators for the treatment of dysmenorrhea: an update. 选择性孕激素受体调节剂治疗痛经：最新进展。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-02-01 Epub Date: 2025-01-16 DOI: 10.1080/14656566.2025.2451145

Anna Rosa Speciale, Kubra Ozpinar, Milo Giani, Dilruba Tureli, Massimiliano Fambrini, Silvia Vannuccini, Felice Petraglia

{"title":"Selective progesterone receptor modulators for the treatment of dysmenorrhea: an update.","authors":"Anna Rosa Speciale, Kubra Ozpinar, Milo Giani, Dilruba Tureli, Massimiliano Fambrini, Silvia Vannuccini, Felice Petraglia","doi":"10.1080/14656566.2025.2451145","DOIUrl":"10.1080/14656566.2025.2451145","url":null,"abstract":"Introduction: Dysmenorrhea is a painful symptom associated with uterine contractions and menstrual bleeding and is treated by administering analgesic drugs. Since progesterone receptors (PRs) have a major role in regulating uterine tissues (myometrium and endometrium) physiology, oral contraceptives are used off-label for treating primary or secondary dysmenorrhea. The development of selective progesterone receptor modulators (SPRMs), a class of synthetic steroids with agonistic, antagonistic, or mixed effects in targeting PRs in different tissues, stimulated their possible clinical use for treating secondary dysmenorrhea related to uterine diseases (endometriosis, adenomyosis, uterine fibroids).Areas covered: The present review examines the development of the clinical trials and observational studies done with the different SPRMs for the treatment of dysmenorrhea in patients with uterine diseases.Expert opinion: Mifepristone, telapristone acetate and vilaprisan have antagonistic activity on PRs, whereas ulipristal acetate and asoprisnil have both potent antagonist and partial agonist effects.Since no studies have been done on primary dysmenorrhea, the different SPRMs have been evaluated in the treatment of endometriosis, adenomyosis and uterine fibroid-related dysmenorrhea.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"257-264"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142978086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacotherapeutic options for coronary thrombosis treatment: where are we today? 冠状动脉血栓治疗的药物治疗选择：我们今天在哪里？

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-02-01 Epub Date: 2025-01-09 DOI: 10.1080/14656566.2025.2450353

Mohammed Ejaz Faizur Rahman, Vidun Wedagedera, William A E Parker, Robert F Storey

{"title":"Pharmacotherapeutic options for coronary thrombosis treatment: where are we today?","authors":"Mohammed Ejaz Faizur Rahman, Vidun Wedagedera, William A E Parker, Robert F Storey","doi":"10.1080/14656566.2025.2450353","DOIUrl":"10.1080/14656566.2025.2450353","url":null,"abstract":"Introduction: Advances in pharmacotherapy for coronary thrombosis treatment and prevention have transformed the clinical outcomes of patients with coronary artery disease but increased the complexity of therapeutic decision-making. Improvements in percutaneous coronary intervention techniques and stent design have reduced the incidence of thrombotic complications, which consequently has increased the challenge of adequately powering clinical trials of novel antithrombotic strategies for efficacy outcomes. Knowledge of the pathophysiology of coronary thrombosis and the characteristics of antithrombotic drugs can help with therapeutic decisions.Areas covered: This review covers the pathophysiology of coronary thrombosis and the mechanisms of action of drugs developed for its treatment, provides an overview of the key issues in decision-making, and highlights key areas for further work in order to guide clinicians on how to individualize risk management and address gaps in the evidence base.Expert opinion: Individualization of antithrombotic therapy regimens has become a vital part of optimizing risk management in people with coronary thrombosis. A critical appraisal of the strengths and limitations of available drugs and the evidence supporting the use of different antithrombotic combinations is intended to provide direction to clinicians and point the way toward further improvements in pharmacotherapy for coronary thrombosis treatment and prevention.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"187-202"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Traditional, alternative, and emerging therapeutics for focal segmental glomerulosclerosis. 局灶节段性肾小球硬化的传统、替代和新兴治疗方法。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-02-01 Epub Date: 2025-01-01 DOI: 10.1080/14656566.2024.2446621

Silvia Di Carlo, Elisa Longhitano, Claudia Spinella, Veronica Maressa, Chiara Casuscelli, Luigi Peritore, Domenico Santoro

{"title":"Traditional, alternative, and emerging therapeutics for focal segmental glomerulosclerosis.","authors":"Silvia Di Carlo, Elisa Longhitano, Claudia Spinella, Veronica Maressa, Chiara Casuscelli, Luigi Peritore, Domenico Santoro","doi":"10.1080/14656566.2024.2446621","DOIUrl":"10.1080/14656566.2024.2446621","url":null,"abstract":"Introduction: Segmental focal glomerulosclerosis is a histological lesion characterized by podocyte damage. It may be a primary disease linked to an unknown circulating factor, secondary to viral infections, drug toxicity, or a disadaptive response to the loss of nephrons, or it may depend on gene mutations or have an indeterminate cause. The treatment of the primary form involves immunosuppressors. Additional pharmacotherapies for residual proteinuria are used, and emerging therapies are being studied to target other pathological pathways.Areas covered: This paper covers the treatment of FSGS, focusing on traditional and emerging therapeutic strategies. It is based on the KDIGO 2021 guidelines and supplemented by a literature search conducted on PubMed.Expert opinion: Treating FSGS is challenging due to its heterogeneity. Immunosuppression is adequate for primary FSGS but harmful in genetic or secondary forms. Key strategies include targeting the underlying cause and using agents that affect renal hemodynamics. Antifibrotic drugs can help slow kidney damage by addressing chronic inflammation and fibrosis. Alongside pharmacological treatments, managing blood pressure and restricting dietary salt are crucial. Finally, personalized treatment requires stratifying patients based on clinical, genetic, and histological data to improve clinical trial design and outcomes.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"179-186"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of alpha-1 adrenergic receptor blockers on erectile function: a systematic review. α -1肾上腺素受体阻滞剂对勃起功能的影响：一项系统综述。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-02-01 Epub Date: 2024-12-30 DOI: 10.1080/14656566.2024.2446628

Ahmed M Bakr, Ahmed I El-Sakka

{"title":"Effects of alpha-1 adrenergic receptor blockers on erectile function: a systematic review.","authors":"Ahmed M Bakr, Ahmed I El-Sakka","doi":"10.1080/14656566.2024.2446628","DOIUrl":"10.1080/14656566.2024.2446628","url":null,"abstract":"Introduction: Alpha-1 adrenergic receptor antagonists (α1-ARAs) are used in the well-established treatment for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS). Since BPH and erectile dysfunction (ED) are commonly concomitant conditions, the importance of addressing the potential role of α1-ARA in patients with ED is rising.Methods: We systemically reviewed literature for studies that assessed erectile function (EF) indices in relation to α1-ARA use. All types of comparisons were included.Results: Out of 1915 records, 21 articles have been included. All the articles suffered high risk of bias. α1-ARA showed a significant improvement in EF in comparison to baseline and placebo. Some α1-ARA are more erectogenic than others. Combined therapy with phosphodiesterase-5 inhibitors improved EF better than either alone. Factors like associated lower urinary symptoms, dose, and duration of therapy modify α1-ARA effects on EF.Conclusion: Αlpha1-ARAs have a potential role in improving EF in subjective and objective scales. However, the available evidence is extracted from studies on patients with other indications for α1-ARAs, particularly BPH-related LUTS. Further investigations should target patients with ED only to precisely identify their clinical utility.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"219-226"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological management of pituitary adenomas - what is new on the horizon? 垂体腺瘤的药物治疗-有什么新进展？

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-02-01 Epub Date: 2025-01-11 DOI: 10.1080/14656566.2024.2446625

Elena V Varlamov, Monica L Gheorghiu, Maria Fleseriu

引用次数: 0

Streptozotocin in pancreatic neuroendocrine tumors: a focus on efficacy and safety. 链脲佐菌素在胰腺神经内分泌肿瘤中的疗效和安全性研究。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-02-01 Epub Date: 2024-12-30 DOI: 10.1080/14656566.2024.2446618

Anna La Salvia, Stefania Bellino, Giuseppe Fanciulli

引用次数: 0

Valbenazine for the treatment of chorea associated with Huntington's disease. 缬苯那嗪用于治疗亨廷顿舞蹈病引起的舞蹈病。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-02-01 Epub Date: 2024-12-30 DOI: 10.1080/14656566.2024.2445728

Jorge Patino, Erin Furr Stimming, Claudia M Testa, Raja Mehanna

{"title":"Valbenazine for the treatment of chorea associated with Huntington's disease.","authors":"Jorge Patino, Erin Furr Stimming, Claudia M Testa, Raja Mehanna","doi":"10.1080/14656566.2024.2445728","DOIUrl":"10.1080/14656566.2024.2445728","url":null,"abstract":"Introduction: Chorea is a motor manifestation of Huntington's disease (HD), which can lead to decreased functional independence and falls. Even though multiple classes of medications have been used to treat this symptom, only the vesicular monoamine transporter 2 (VMAT2) inhibitors tetrabenazine, deutetrabenazine, and valbenazine have been approved by the FDA for this indication.Areas covered: This article reviews the pharmacological properties, clinical efficacy, safety, and tolerability of valbenazine in the treatment of chorea in HD. Key considerations in the concomitant use of VMAT2 inhibitors with other medications are discussed, particularly considerations specific to valbenazine use plus medications often used to treat neuropsychiatric symptoms in HD.Expert opinion: Valbenazine effectively addresses chorea. Its selectivity avoids VMAT1-related side effects and tardive dyskinesia and may result in less off-target side effects such as parkinsonism, behavioral changes, and akathisia. The cost of this medication could be a barrier to access, even for those with insurance, due to high co-pay fees. Head-to-head clinical trials are needed to compare valbenazine's efficacy with the other approved drugs for chorea in HD.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"127-132"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacotherapy of type 1 diabetes - part 1: yesterday. 1型糖尿病的药物治疗-第一部分：昨天。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-02-01 Epub Date: 2025-01-28 DOI: 10.1080/14656566.2025.2454280

Marc Rendell

{"title":"Pharmacotherapy of type 1 diabetes - part 1: yesterday.","authors":"Marc Rendell","doi":"10.1080/14656566.2025.2454280","DOIUrl":"10.1080/14656566.2025.2454280","url":null,"abstract":"Introduction: Type 1 diabetes is a unique autoimmune attack on the β cell of the pancreatic islet resulting in progressive destruction of these cells and as a result the ability of the body to maintain insulin production. The consequences of insulin deficiency are very severe, and the disease was fatal prior to the ability to extract insulin from animal pancreas in 1921. We review progress in the treatment of childhood type 1 diabetes over the past 100 years.Areas covered: We used PubMed and standard search engines to search for the evolution of diagnosis and treatment of type 1 diabetes.Expert opinion: Insulin replacement proved lifesaving for children afflicted with type 1 diabetes. However, it was observed that these children suffered from microvascular and large vessel disease. The Diabetes Control and Complications Trial (DCCT) with its extension Epidemiology of Diabetes Interventions and Complications Trial (EDIC) proved that control of blood glucose as close to normal as possible could prevent these diabetes-related conditions. Many formuations of insulin with varying onset and duration of action have been developed; yet normalization of glucose levels is difficult due to hypoglycemic events. There is continued progress toward that goal.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"313-324"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Juvenile animal studies in human drug development. 人类药物开发中的幼年动物研究。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-02-01 Epub Date: 2025-01-21 DOI: 10.1080/14656566.2025.2456589

Paul Baldrick

引用次数: 0